MOLN News and Press, Molecular Partners AG From 05/13/25

2025-05-13 01:18:58 ET Summary Molecular Partners basically uses DARPins as a modular alternative to monoclonal antibodies in oncology. Their Radio-DARPin collaboration with Orano Med will now use lead-212 for highly localized alpha therapy candidates. However, Novartis droppe...

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano Med ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the &...

Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First preclinical data on second 212 Pb-based Radio-DARPin co-develo...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annua...

2025-03-07 12:25:19 ET More on markets Dividend Roundup: Nvidia, Amgen, Home Depot, JD.com, and more February nonfarm payrolls rise slightly less than expected Trump establishes Strategic Bitcoin Reserve Is the S&P 500 a buying opportunity? Oppenheimer hi...

2025-03-07 11:59:35 ET Molecular Partners AG (MOLN) Q4 2024 Earnings Conference Call March 07, 2025 08:00 AM ET Company Participants Michael Tobias Stumpp - EVP Projects Patrick Amstutz - Co-Founder & CEO Philippe Legenne - Chief Medical Officer Robert He...

2025-03-06 17:00:16 ET More on Molecular Partners Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs Molecular Partners & Orano Med join hands for alpha radio-therapies for cancer Seeking Alpha’s Quant Rating on Molecular Pa...

2025-03-06 16:49:50 ET More on Molecular Partners Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs Molecular Partners & Orano Med join hands for alpha radio-therapies for cancer Seeking Alpha’s Quant Rating on Molecular Pa...

DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearance Strategic partnership with Orano Med on Radio-DARPins now expanded to ten programs MP0533 Phase 1/2a clinical data show improved response rate and depth in ongoing cohort, additional dos...